XRTX:CA:TSV-XORTX Therapeutics Inc (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.95

Change

-0.12 (-2.95)%

Market Cap

USD 0.02B

Volume

1.70K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.17 (+7.87%)

USD 0.16B
ARCH:CA Arch Biopartners Inc

+0.01 (+0.57%)

USD 0.11B
MIR:CA MedMira Inc

-0.01 (-5.26%)

USD 0.05B
NRX:CA NurExone Biologic Inc.

-0.01 (-1.67%)

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

-0.02 (-2.78%)

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

-0.22 (-17.89%)

USD 0.03B
CZO:CA Ceapro

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

+0.01 (+4.00%)

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B

ETFs Containing XRTX:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 36.21% 63% D 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.21% 63% D 77% C+
Trailing 12 Months  
Capital Gain -94.39% 5% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -94.39% 5% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -38.84% 9% A- 3% F
Dividend Return -38.84% 9% A- 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.17% 57% F 58% F
Risk Adjusted Return -99.17% 13% F 11% F
Market Capitalization 0.02B 61% D- 66% D+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.